当前位置:
首页 > 科普 > 她说+癌症·新知+癌症·真相(套装共3册)pdf/doc/txt格式电子书下载

她说+癌症·新知+癌症·真相(套装共3册)pdf/doc/txt格式电子书下载

本站仅展示书籍部分内容

如有任何咨询

请加微信10090337咨询

她说+癌症·新知+癌症·真相(套装共3册)pdf/doc/txt格式电子书下载

书名:她说+癌症·新知+癌症·真相(套装共3册)pdf/doc/txt格式电子书下载

推荐语:

作者:李治中著

出版社:清华大学出版社

出版时间:2019-03-01

书籍编号:30500728

ISBN:

正文语种:中文

字数:435230

版次:1

所属分类:科学新知-科普

全书内容:

参考文献


[1]Metzger M J,et al.Horizontal transmission of clonal cancer cells causes leukemia in soft-shell clams[J].Cell,2015,161(2):255-263.


[2]Zhou C.Lung cancer molecular epidemiology in China:recent trends[J].Transl Lung Cancer Res.2014,3(5):270-279.


[3]Yock T I,et al.Quality of life outcomes in proton and photon treated pediatric brain tumor survivors[J].Radiother Oncol,2014,113(1):89-94.


[4]Yadav M,et al.Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing[J].Nature,2014,515(7528):572-576.


[5]Warren G W,et al.The 2014 Surgeon General’s report:“The health consequences of smoking — 50 years of progress”:a paradigm shift in cancer care[J].Cancer,2014,120(13):1914-1916.


[6]Solomon B J,et al.First-line crizotinib versus chemotherapy in ALK-positive lung cancer[J].N Engl J Med,2014,371(23):2167-2177.


[7]Snyder A,et al.Genetic basis for clinical response to CTLA-4 blockade in melanoma[J].N Engl J Med,2014,371(23):2189-2199.


[8]Shi Y,et al.A prospective,molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology(PIONEER) [J].J Thorac Oncol,2014,9(2):154-162.


[9]Shen L,Ji H F.Ceritinib in ALK-rearranged non-small-cell lung cancer[J].N Engl J Med,2014,370(26):2537.


[10]Shaw A T,Engelman J A.Ceritinib in ALK-rearranged non-small-cell lung cancer[J].N Engl J Med,2014,370(26):2537-2539.


[11]Sayin V I,et al.Antioxidants accelerate lung cancer progression in mice[J].Sci Transl Med,2014,6(221):221ra15.


[12]Mitin T A,Zietman L.Promise and pitfalls of heavy-particle therapy[J].J Clin Oncol,2014,32(26):2855-2863.


[13]Mendenhall N P,et al.Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer[J].Int J Radiat Oncol Biol Phys,2014,88(3):596-602.


[14]Maude S L,et al.Chimeric antigen receptor T cells for sustained remissions in leukemia[J].N Engl J Med,2014,371(16):1507-1517.


[15]Lin Y,et al.Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers[J].Proc Natl Acad Sci U S A,2014,111(42):E4504-4512.


[16]Herbst R S,et al.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J].Nature,2014,515(7528):563-567.


[17]Gubin M M,et al.Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens[J].Nature,2014,515(7528):577-581.


[18]Gragert L,et al.HLA match likelihoods for hematopoietic stem-cell grafts in the U.S.registry[J].N Engl J Med,2014,371(4):339-348.


[19]Brastianos K,et al.Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas[J].Nat Genet,2014,46(2):161-165.


[20]Bonadies D C,et al.Adverse events in cancer genetic testing:the third case series[J].Cancer J,2014,20(4):246-53.


[21]Retraction notice to “Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize”Food Chem Toxicol,2014,63:244.


[22]Wolchok J D,et al.Nivolumab plus ipilimumab in advanced melanoma[J].N Engl J Med,2013,369(2):122-133.


[23]Watson I R,et al.Emerging patterns of somatic mutations in cancer[J].Nat Rev Genet,2013,14(10):703-718.


[24]Vacchelli E,et al.Trial watch:Oncolytic viruses for cancer therapy[J].Oncoimmunology,2013,2(6):e24612.


[25]Shi Y,et al.Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer(ICOGEN):a randomised,double-blind phase 3 non-inferiority trial[J].Lancet Oncol,2013,14(10):953-961.


[26]Nixon I J,et al.The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer,based on Memorial Sloan-Kettering Cancer Center risk group stratification[J].Thyroid,2013,23(6):683-694.


[27]Li Y,et al.Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer[J].PLoS One,2013,8(1):e52093.


[28]Lawrence M S,et al.Mutational heterogeneity in cancer and the search for new cancer-associated genes[J].Nature,2013,499(7457):214-218.


[29]Hamid O,et al.Safety and tumor responses with lambrolizumab(anti-PD-1) in melanoma[J].N Engl J Med,2013,369(2):134-144.


[30]Chung C S,et al.Incidence of second malignancies among patients treated with proton versus photon radiation[J].Int J Radiat Oncol Biol Phys,2013,87(1):46-52.


[31]Arcila M E,et al.EGFR exon 20 insertion mutations in lung adenocarcinomas:prevalence,molecular heterogeneity,and clinicopathologic characteristics[J].Mol Cancer Ther,2013,12(2):220-229.


[32]Wang Y C,et al.Comparison of Cancer Incidence between China and the USA[J].Cancer Biol Med,2012,9(2):128-132.


[33]Topalian S L,et al.Safety,activity,and immune correlates of anti-PD-1 antibody in cancer[J].N Engl J Med,2012,366(26):2443-2454.


[34]Seralini G E,et al.Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize[J].Food Chem Toxicol,2012,50(11):4221-4231.


[35]Lim S S,et al.A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions,1990-2010:a systematic analysis for the Global Burden of Disease Study 2010[J].Lancet,2012,380(9859):2224-2260.


[36]Govindan R,et al.Genomic landscape of non-small cell lung cancer in smokers and never-smokers[J].Cell,2012,150(6):1121-1134.


[37]An S J,et al.Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status[J].PLoS One,2012,7(6):e40109.


[38]Zava T T,Zava D T.Assessment of Japanese iodine intake based on seaweed consumption in Japan:A literature-based analysis[J].Thyroid Res,2011,4:14.


[39]Wagle N,et al.Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling[J].J Clin Oncol,2011,29(22):3085-3096.


[40]Sequist L V,et al.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors[J].Sci Transl Med,2011,3(75):75ra26.


[41]Ramaekers B L,et al.Systematic review and meta-analysis of radiotherapy in various head and neck cancers:comparing photons,carbon-ions and protons[J].Cancer Treat Rev,2011,37(3):185-201.


[42]Pederson T,Mukherjee S.The Emperor of All Maladies A Biography of Cancer[J].Science,2011,332(6028):423-423.


[43]Moeller B J,et al.Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy[J].Radiat Oncol,2011,6:58.


[44]Miller L H,Su X.Artemisinin:discovery from the Chinese herbal garden[J].Cell,2011,146(6):855-858.


[45]Kantoff W,et al.Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J].N Engl J Med,2010,363(5):411-422.


[46]Domchek S M,et al.Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality[J].JAMA,2010,304(9):967-975.


[47]Sawka A M,et al.Second primary malignancy risk after radioactive iodine treatment for thyroid cancer:a systematic review and meta-analysis[J].Thyroid,2009,19(5):451-457.


[48]Little M P.Cancer and non-cancer effects in Japanese atomic bomb survivors[J].J Radiol Prot,2009,29(2A):A43-59.


[49]Lawenda B D,et al.Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?[J].J Natl Cancer Inst,2008,100(11):773-783.


[50]Dishop M K,Kuruvilla S.Primary and metastatic lung tumors in the pediatric population:a review and 25-year experience at a large children’s hospital[J].Arch Pathol Lab Med,2008,132(7):1079-1103.


[51]Ballen K K,et al.Collection and preservation of cord blood for personal use[J].Biol Blood Marrow Transplant,2008,14(3):356-363.


[52]Schoder H,Gonen M.Screening for cancer with PET and PET/CT:potential and limitations[J].J Nucl Med,2007,48 Suppl 1:4S-18S.


[53]McLaughlin J R,et al.Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations:a case-control study[J].Lancet Oncol,2007,8(1):26-34.


[54]Kelly E,Russell S J.History of oncolytic viruses:genesis to genetic engineering[J].Mol Ther,2007,15(4):651-659.


[55]Eapen M,et al.Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia:a comparison study[J].Lancet,2007,369(9577):1947-1954.


[56]Bjelakovic G,et al.Mortality in randomized trials of antioxidant supplements for primary and secondary prevention:systematic review and meta-analysis[J].JAMA,2007,297(8):842-857.


[57]Pearse A M,Swift K.Allograft theory:transmission of devil facial-tumour disease[J].Nature,2006,439(7076):549.


[58]Murgia C,et al.Clonal origin and evolution of a transmissible cancer[J].Cell,2006,126(3):477-487.


[59]Garber K.China approves world’s first oncolytic virus therapy for cancer treatment[J].J Natl Cancer Inst,2006,98(5):298-300.


[60]Druker B J,et al.Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia[J].N Engl J Med,2006,355(23):2408-2417.


[61]Lundkvist J,et al.Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma[J].Cancer,2005,103(4):793-801.


[62]Ludwig J A,Weinstein J N.Biomarkers in cancer staging,prognosis and treatment selection[J].Nat Rev Cancer,2005,5(11):845-856.


[63]van der Zee,J.Heating the patient:a promising approach?[J].Ann Oncol,2002,13(8):1173-1184.


[64]Srivastava S R.Gopal-Srivastava,Biomarkers in cancer screening:a public health perspective[J].J Nutr,2002,132(8 Suppl):2471S-2475S.


[65]Miralbell R,et al.Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors[J].Int J Radiat Oncol Biol Phys,2002,54(3):824-829.


[66]Nishimura H,et al.Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor[J].Immunity,1999,11(2):141-151.


[67]Patterson R E,et al.Vitamin supplements and cancer risk:the epidemiologic evidence[J].Cancer Causes Control,1997,8(5):786-802.


[68]Jha P,et al.The antioxidant vitamins and cardiovascular disease.A critical review of epidemiologic and clinical trial data[J].Ann Intern Med,1995,123(11):860-872.


[69]Ferrara J L,Abhyankar S,Gillilan

....

本站仅展示书籍部分内容

如有任何咨询

请加微信10090337咨询

本站仅展示书籍部分内容
如有任何咨询

请加微信10090337咨询

再显示